The FDA's drug approvals database lists a supplement dated 19 October to abbreviated new drug application 211598 for voriconazole, held by Hetero Labs. Supplements to generic applications usually cover manufacturing, labelling alignment or packaging changes. The database entry does not state the nature of this change.
This is an administrative action, not a new indication or a safety communication. Hetero is an Indian manufacturer, so the product line is likely familiar to Indian hospitals, but this US action has no direct bearing on CDSCO status.
- Treat this as an administrative US regulatory change with no new clinical guidance.
- Continue therapeutic drug monitoring of voriconazole as standard practice.
- Check for interactions with azole-sensitive drugs, which remain the main voriconazole hazard.
Why it matters
Regulatory listings can look like news; this one is not a safety signal.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free